Malcolm Sim · Sep 9, 2024 · 8:10 AM UTC

Malcolm Sim · Sep 9, 2024 · 8:10 AM UTC

Malcolm Sim

9 Sep 2024

Exciting work by @AmirHorowitz and team! Congrats to all. HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer biorxiv.org/content/10.1101/…

HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder...

Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is the primary treatment for non-muscle-invasive bladder cancer (NMIBC), known to stimulate inflammatory cytokines, notably interferon (IFN)-γ. We...

biorxiv.org

Sep 9, 2024 · 8:10 AM UTC

1,532

Sort replies: Relevant Recent Liked